Neil Walsh received his BSc in Chemistry, and MSc in Pharmaceutical Analysis from Glasgow Caledonian University (UK) and the University of Strathclyde (Glasgow, UK) respectively. He has over 5 years’ experience as a bioanalytical Research Scientist at Aptuit (Edinburgh, United Kingdom) and Tepnel Scientific Services (Glasgow, United Kingdom), and a further 5 years’ in Account Management at both Agilent Technologies (CA, USA) and PerkinElmer (MA, USA). Neil joined SCIEX (MA, USA) in 2013 as a Senior Sales Representative and is currently the Global Marketing Manager for Pharma where he oversees the development of all pharma marketing activity.
Questions
1 Could you briefly introduce yourself and your institution? [Time – 00:35]
2 SCIEX recently announced the launch of the new Acoustic Ejection Mass Spectrometry technology. Could you describe how this technology works and what sets it apart from other mass spectrometry technologies? [Time – 01:08]
3 SCIEX also launched the Triple Quad 5500+ LC–MS/MS system – QTRAP ready. What is unique about this instrument and how is it able to deliver high data confidence? [Time – 05:06]
4 The final system that was introduced was the TripleTOF 6600+ LC–MS/MS with scanning SWATH acquisition and OneOmics in the SCIEX cloud. How is this latest model an improvement on previous TripleTOF systems released by SCIEX? [Time – 07:00]
5 Why are technological advancements so important in progressing our scientific knowledge? [Time – 08:42]
6 Looking to the future, what new instrumentation and/or technologies can we expect to see from SCIEX in the next few years? [Time – 10:27]
